Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks o
ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...
Source: europapress.es